ArticleJournal of computer-aided molecular design2026
MsDGCN: multi-scale diffusion graph convolutional network for the prediction of drug-disease association.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal machine learning and deep graph neural networks for the prediction of molecular inhibitory activity and disease associations.Journal of computer-aided molecular design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Drug-disease association prediction is crucial for accelerating drug repurposing, yet existing computational models largely focus on integrating biological attributes while neglecting topological regulatory patterns within heterogeneous biological networks. To address this, we propose MsDGCN, a novel multi-scale diffusion graph convolutional network. The model is built upon two key innovations: a multi-scale architecture that captures complex topological signals through meta-path guided diffusion and cross-path attention mechanisms, and a dedicated hard negative mining strategy that selects biologically plausible confounders to sharpen the decision boundary. To handle severe data imbalance, an XGBoost classifier with dynamic class weighting is integrated to model nonlinear feature interactions. Extensive ten-fold cross-validation demonstrates that MsDGCN significantly outperforms state-of-the-art baselines across key metrics, confirming its capability to effectively leverage network topology for improved drug-disease association prediction. MsDGCN provides a robust and generalizable framework for predicting drug-disease associations. Code and data are available at: https://github.com/CDMBlab/MsDGCN.
Indexed as
Identifiers
41954832What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.